A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name Ozempic — may help reduce not only alcohol cravings, but the amount of alcohol ...

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

Market uncertainty makes investors nervous about investing in speculative industries. But Wall Street has high hopes for ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

7 has achieved the British Standards Institute (BSI) surveillance audit certification following a recent SOC II Type I compliance certification LONDON, Jan. 29, 2025 /PRNewswire/ -- Image Analysis ...

"Having such comprehensive quality compliance allows IAG to partner with companies seeking effective imaging biomarkers to support safety and efficacy of their drug candidates in clinical trials ...

As the company progresses through clinical trials and approaches potential regulatory milestones, a comprehensive analysis of its stock reveals both opportunities and challenges in the evolving ...

The pharmaceutical industry is known for its high-risk and high-reward nature, with clinical trial outcomes being a significant driver of stock performance. The news of volenrelaxin's trial ...